Tipiramato [Spanish] en es it fr

Categoria

Tipiramato [Spanish] Nombres de marca, Tipiramato [Spanish] Analogos

Tipiramato [Spanish] Marca los nombres de mezcla

  • No information avaliable
  • Tipiramato [Spanish] Formula quimica

    C12H21NO8S

    Tipiramato [Spanish] RX enlace

    http://www.rxlist.com/cgi/generic2/topiram.htm

    Tipiramato [Spanish] FDA hoja

    Tipiramato_[Spanish] FDA

    Tipiramato [Spanish] MSDS (hoja de seguridad de materiales)

    Tipiramato_[Spanish] MSDS

    Tipiramato [Spanish] Sintesis de referencia

    No hay información disponible

    Tipiramato [Spanish] Peso molecular

    339.363 g/mol

    Tipiramato [Spanish] Punto de fusion

    No information avaliable

    Tipiramato [Spanish] H2O Solubilidad

    9,8 mg / ml

    Tipiramato [Spanish] Estado

    Solid

    Tipiramato [Spanish] LogP

    0.712

    Tipiramato [Spanish] Formas de dosificacion

    Cápsula (15 y 25 mg cápsulas de espolvorear); Tablet (25, 50, 100 y 200 mg)

    Tipiramato [Spanish] Indicacion

    Se utiliza para el tratamiento y control de las crisis parciales y graves convulsiones tónico-clónicas (gran mal) y también para la prevención de la migraña. En los niños también se utiliza para el tratamiento del síndrome de Lennox-Gastaut.

    Tipiramato [Spanish] Farmacologia

    El topiramato es un anticonvulsivante indicado en el tratamiento de la epilepsia y la migraña. El topiramato mejora la GABA-activa los canales de cloruro. Además, el topiramato inhibe la neurotransmisión excitatoria, a través de acciones de kainato y AMPA. Existe evidencia de que el topiramato tiene un efecto específico sobre GluR5 receptores de kainato. También es un inhibidor de la anhidrasa carbónica, en particular los subtipos II y IV, pero esta acción es débil y probablemente no guarden relación con sus acciones anticonvulsivantes, pero puede explicar el mal gusto y el desarrollo de cálculos renales observados durante el tratamiento. Su posible efecto como estabilizador del humor parece ocurrir antes de cualidades anticonvulsivantes en dosis bajas. Topiramato inhibe electroshock máximo y las convulsiones inducidas por pentilentetrazol así como parcial y secundarily generalizadas tónico-clónicas en el modelo de kindling, los resultados de predective de un amplio espectro de las actividades de las convulsiones clínicamente.

    Tipiramato [Spanish] Absorcion

    Rápida con pleak concentraciones plasmáticas después de 2 horas y una biodisponibilidad del 80%.

    Tipiramato [Spanish] Toxicidad

    Los síntomas de sobredosis incluyen dolor abdominal, agitación, visión borrosa, convulsiones, depresión, mareos, visión doble, somnolencia, pérdida de la coordinación, la actividad mental reducido, presión arterial baja, disminución de la consciencia, diarrea severa, la lentitud, y problemas del habla.

    Tipiramato [Spanish] Informacion de Pacientes

    Topamax is an antiepileptic drug, prescribed to control both the mild attacks known as partial seizures and the severe tonic-clonic convulsions known as grand mal seizures. It is typically added to the treatment regimen when other drugs fail to fully control a patient's attacks.

    Topamax is also prescribed for the prevention of migraine headaches (also known as prophylactic treatment). However, due to a lack of studies, it's not known whether the drug can treat acute migraine attacks.

    Because Topamax sometimes causes confusion, dizziness, fatigue, and problems with coordination and concentration, you should not drive, operate machinery, or participate in any hazardous activity that requires full mental alertness until you are certain how the drug affects you.

    Topamax has been known to cause a potentially serious condition known as metabolic acidosis (an increase of acid in the blood). In children, chronic metabolic acidosis may affect growth or cause rickets (a softening or weakness of the bones that can lead to bone deformities). Contact your doctor immediately if you experience symptoms of metabolic acidosis such as rapid breathing, an irregular heartbeat, confusion, lethargy, fatigue, or loss of appetite. Your doctor will decide if you should discontinue taking Topamax. Do not abruptly stop taking Topamax on your own; your doctor will gradually taper the dosage to avoid an increase in seizures.

    Topamax has been known to trigger severe nearsightedness along with increased pressure inside the eye. The problem usually occurs within 1 month of starting treatment. If you develop blurred vision or eye pain, call your doctor immediately. Discontinuation of the drug may be necessary to prevent permanent vision loss.

    In children with chronic diarrhea or untreated kidney disorders, use of Topamax may lead to rickets and reduced growth rates.

    Tell your doctor if you have kidney problems or if you are on hemodialysis; your dosage of Topamax may need adjustment. Elderly patients in particular may experience reduced kidney function when taking Topamax. Also make sure the doctor is aware of any liver disorder you may have. Topamax must be used cautiously by individuals with impaired liver function.

    Anyone using Topamax, particularly children, should be carefully monitored by their doctor for signs of increased body temperature or decreased sweating, especially during hot weather.

    In rare instances, suicide attempts have been reported in people taking Topamax.

    Tipiramato [Spanish] Organismos afectados

    Humanos y otros mamíferos